Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Checkpoint Therapeutics, Inc. (CKPT : NSDQ)
 
 • Company Description   
Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.85 Daily Weekly Monthly
20 Day Moving Average: 2,285,704 shares
Shares Outstanding: 79.18 (millions)
Market Capitalization: $225.67 (millions)
Beta: 1.53
52 Week High: $5.38
52 Week Low: $1.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.62% 8.43%
12 Week -9.24% -14.99%
Year To Date 7.55% -4.77%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 GANSEVOORT STREET 9TH FLOOR
-
NEW YORK,NY 10014
USA
ph: 781-652-4500
fax: -
ir@checkpointtx.com http://www.checkpointtx.com
 
 • General Corporate Information   
Officers
James F. Oliviero - Chief Executive Officer; President and Director
Michael S. Weiss - Chairman
Garrett Gray - Chief Financial Officer
Lindsay A. Rosenwald - Director
Scott Boilen - Director

Peer Information
Checkpoint Therapeutics, Inc. (CORR.)
Checkpoint Therapeutics, Inc. (RSPI)
Checkpoint Therapeutics, Inc. (CGXP)
Checkpoint Therapeutics, Inc. (BGEN)
Checkpoint Therapeutics, Inc. (GTBP)
Checkpoint Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 162828107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/04/21
Share - Related Items
Shares Outstanding: 79.18
Most Recent Split Date: (:1)
Beta: 1.53
Market Capitalization: $225.67 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.43 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.16
Price/Cash Flow: -
Price / Sales: 1,367.72
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: 47.06%
Sales Growth
vs. Year Ago Period: -93.00%
vs. Previous Quarter: 151.85%
ROE
03/31/21 - -74.75
12/31/20 - -89.81
09/30/20 - -100.54
ROA
03/31/21 - -62.13
12/31/20 - -70.40
09/30/20 - -75.09
Current Ratio
03/31/21 - 8.47
12/31/20 - 5.90
09/30/20 - 6.64
Quick Ratio
03/31/21 - 8.47
12/31/20 - 5.90
09/30/20 - 6.64
Operating Margin
03/31/21 - -15,942.43
12/31/20 - -2,159.12
09/30/20 - -2,032.05
Net Margin
03/31/21 - -15,942.43
12/31/20 - -2,159.12
09/30/20 - -2,032.05
Pre-Tax Margin
03/31/21 - -15,942.42
12/31/20 - -2,159.12
09/30/20 - -2,032.05
Book Value
03/31/21 - 0.68
12/31/20 - 0.51
09/30/20 - 0.53
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
Debt-to-Capital
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
 

Powered by Zacks Investment Research ©